Oral vaccine against gram negative bacterial infection

Details Oral vaccine against gram negative bacterial infection Oral vaccine against gram negative bacterial infection

1995-06-07

1998-03-24

Siderry, Hazel F.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

4242581, 4242551, 4242611, 4242491, 42419711, 424450, A61K 3908, A61K 39112, A61K 9127

Patent

active

057309892

ABSTRACT:
The present invention concerns an oral preparation useful as an immunizing agent or vaccine against gram negative bacterial infection. This oral preparation can also be used as a treatment for those infected with gam negative bacteria. The preparations can be used against any gram negative bacterial infection, including Escherichia coli, Shigella flexneri 2a, and Salmonella enteriditis.

REFERENCES:
patent: 4235871 (1980-11-01), Papahadjopoulos
patent: 5009819 (1991-04-01), Popescu et al.
Gregoriadis, G. (1990) "Immunological adjuvants: a role for liposomes" Immunology Today 11:89-97.
Ostro, M.J. (1987) "Liposomes" Scientific American 256(1):102-111.
Caprioli, A. et al. "Hemolytic-Uremic Syndrome and Vero Cytotoxin-Producing"Escherichia coli Infection in Italy'Infectious Diseases 166:154-158 (Jul. 1992).
Chart, H. et al. "Antibodies to Escherichia coli 0157 in patients with haemorrhagic colitis and haemolytic uraemic syndrome"J. Clin. Pathol. 42:973-976 (1989).
Chart, H et al. "Serological identification of Escherichia coli 0157:H7 infection in haemolyitc uraemic syndrome" The Lancet 337:138-40 (19 Jan. 1991).
Cross, A.S. et al. "Use of monoclonal antibody combinations in the prevention of bacteremia caused by Escherichia coli" Serodiagnosis and Immunotherapy in Infectious Disease 2:127-136 (1988).
Doyle, M.P. and J.L. Schoeni "Isolation of Escherichia coli 0157:H7 from Retail Fresh Meats and Poultry" Applied and Environmental Microbiology 53(1):2394-2396 (Oct. 1987).
Edelman, R. et al. "Summary of the International Symposium and Workshop on Infections Due to Verocytotoxin (Shiga-Like Toxin)-Producing Escherichia coli" J. Infectious Diseases 157(5):1102-1104 (May 1988).
Kaufman, B.M. et al. "Monoclonal Antibodies Reactive with K1-Encapsulated Escherichia coli Lipopolysaccharide are Opsonic and Protect Mice against Lethal Challenge" Infection and Immunity 52(2):617-619 (May 1986).
Kim, K.S. et al. "Functional Activities of Monoclonal Antibodies to the O Side Chain of Escherichia coli Lipopolysaccharides in Vitro and in Vivo" Infectious Diseases 157(1):47-53 (Jan. 1988).
Konowalchuk, J. et al. "Vero Response to a Cytotoxin of Escherichia coli " Infection and Immunity 18(3);775-779 (Dec. 1977).
Lopez, E.L. et al. "Evidence of infection with organisms producing Shiga-like toxins in household contacts of children with the hemolytic uremic syndrome" Pediatric Infectious Disease J. 10(1):20-24 (1991).
March, S.B. and S. Ratnam "Latex Agglutination Test for Detection of Escherichia coli Serotype 0157" J. Clinical Microbiology 27(7):1675-1677 (Jul. 1989).
March, S.B. and S. Ratnam "Sorbitol-MacConkey Medium for Detection of Escherichia coli 0157:H7 Associated with Hemorrhagic Colitis" J. Clinical Microbiology 23(5):869-872 (May 1986).
Ogasawara, T. et al. "Inhibition of protein synthesis by Vero toxin (VT2 or Shiga-like toxin II) produced by Escherichia coli 0157:H7 at the level of elongation factor 1-dependent aminoacyl-tRNA binding to ribosomes" Microbial Pathogenesis 4:127-135 (1988).
Pai, C.H. et al. "Sporadic Cases of Hemorrhagic Colitis Associated with Escherichia coli 0157:H7" Annals of Internal Medicine 101(6):738-742 (Dec. 1984).
Remis, R.S. et al. "Sporadic Cases of hemorrhagic Colitis Associated with Escherichia coli 0157:H7" Annals of Internal Medicine 101(5):624-626 (Nov. 1984).
Riley, L.W. "The Epidemiologic, Clinical, and Microbiologic Features of Hemorrhagic Colitis" Ann. Rev. Microbiol. 41:383-407 (1987).
Sadoff, J.C. et al. "Characterization of Mouse Monoclonal Antibodies Directed against pseudomonas aeruginosa Lipopolysaccharides" Antibiot. Chemother. 36:134-146 (1985).
Scotland, S.M. et al. "Two Distinct Toxins Active On Vero Cells From Escherichia Coli 0157" The Lancet ii:885-886 (19 Oct. 1985).
Varanelli, C. et al. "Non-Phospholipid Vesicles as Experimental Immunological Adjuvants" in Liposome Technology, 2nd Ed., vol. I: Liposome Preparation and Related Techniques, G. Gregoriadis (ed.) (Ann Arbor, MI: CRC Press, Inc., 1993) Chp. 17, 253-264.
Wallach, D.F.H. and R. Mathur "Non-Phospholipid Liposomes: Principles and Bulk Applications" in Liposome Technology, 2nd Ed., vol. I: Liposome Preparation and Related Techniques, G. Gregoriadis (ed.) (Ann Arbor, MI: CRC Press, Inc., 1993) Chp. 16, 241-252.
Wallach, D.F.H. and J.R. Philippot "New Type of Lipid Vesicle: Novasome.TM." in Liposome Technology, 2nd Ed., vol. I: Liposome Preparation and Related Techniques, G. Gregoriadis (ed.) (Ann Arbor, MI: CRC Press, Inc., 1993) Chp. 9, 142-156.
McQueen et al Gastroentenology 104:A742, 1993 Abstract.
Bergarmann et al Rev Infect Dis:10:939-950 1989.
Varanelli et al, Liposmoe Preparation & Related Techiques, Chapter 17 pp. 253-264, 1993.
Bergmann, K. and Waldman, R., "Stimulation of Secretory Antibody Following Oral Administration of Antigen, " Reviews of Infectious Diseases, vol. 10, No. 5, 939-950 (1988).

Affiliated with

Also associated with

Rating

Oral vaccine against gram negative bacterial infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral vaccine against gram negative bacterial infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral vaccine against gram negative bacterial infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2286751